

**37.** An isolated polypeptide according to claim **36**, wherein the polypeptide sequence is selected from the group consisting of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and sequence substantially equivalent thereto.

**38.** An isolated polypeptide according to claim **36** or **37**, fused to an antibody or fragment capable of transmigrating the blood brain barrier.

**39.** A isolated polypeptide according to claim **36** or **37**, further comprising an antibody or fragment capable of transmigrating the blood brain barrier.

**40.** A isolated polypeptide according to claim **36** or **37**, further comprising an Fc fragment.

**41.** A fusion protein comprising an antibody or fragment thereof selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO: 25, SEQ ID NO:26; a polypeptide that binds b-amyloid selected from the group consisting of SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38; and an Fc fragment selected from the group consisting of SEQ ID NO: SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41.

**42.** A fusion protein according to claim **41**, wherein the fusion protein further comprises a linker peptide (for example GGGSGGGGS); wherein the fusion protein is a single chain polypeptide.

**43.** A fusion protein according to claim **42**, wherein the fusion protein forms a dimeric polypeptide.

**44.** A composition comprising the fusion protein of any one of claims **41** to **43**, and a pharmacologically acceptable carrier.

**45.** A fusion protein of any one of claims **41** to **43**, comprising an Fc with attenuated effector functions.

**46.** A nucleic acid, or vector comprising a nucleic acid, encoding a fusion protein of any one of claims **41** to **43** and **45**.

**47.** A pharmaceutical composition comprising the isolated polypeptide of any one of claims **36** to **40**, and a pharmaceutically acceptable diluent, carrier, vehicle or excipient for ameliorating the symptoms of Alzheimer's disease.

**48.** A pharmaceutical composition of claim **47** for use in reducing toxic  $\beta$ -amyloid levels in the brains of subjects having increased levels of brain amyloid beta.

**49.** A method of reducing toxic  $\beta$ -amyloid levels in the brains of subjects having increased levels of brain amyloid beta comprising the step of introducing a pharmaceutical composition of claim **48** into a subject's body.

\* \* \* \* \*